Live Quote · NASDAQICPTHealthcare· Biotechnology

Intercept Pharmaceuticals, Inc.

$19.00 0.21%(+$0.04)
TickerSpark Score
74/100
Solid
80
Valuation
80
Profitability
55
Growth
56
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICPT research report →

52-Week Range78% of range
Low
$8.82
Current
$19.00
High
$21.86
Company Overviewwww.interceptpharma.com

About the company

Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada.

CEO
Jerome B. Durso
IPO
2012
Employees
341
HQ
New York City, NY, US

Price Chart

+21.02% · this period
$21.71$15.44$9.17Nov 14May 17Nov 14
Valuation
Market Cap
$794.69M
P/E
5.57
P/S
2.78
P/B
6.90
EV/EBITDA
-17.45
Div Yield
0.00%
Profitability
Gross Margin
99.66%
Op Margin
-23.88%
Net Margin
40.31%
ROE
-253.45%
ROIC
10.37%
Growth & Income
Revenue
$285.71M · -21.39%
Net Income
$115.17M · 179.42%
EPS
$3.41 · 174.95%
Op Income
$-68,216,000
FCF YoY
34.94%
Performance & Tape
52W High
$21.86
52W Low
$8.82
50D MA
$15.66
200D MA
$14.71
Beta
0.88
Avg Volume
2.05M

Get TickerSpark's AI analysis on ICPT

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Nov 8, 23AKKARAJU SRINIVASsell8,111
Nov 8, 23AKKARAJU SRINIVASsell2,174
Nov 8, 23AKKARAJU SRINIVASsell2,966
Nov 8, 23AKKARAJU SRINIVASsell12,089
Nov 8, 23AKKARAJU SRINIVASsell12,790
Nov 8, 23AKKARAJU SRINIVASsell12,547
Nov 8, 23AKKARAJU SRINIVASsell275
Nov 8, 23AKKARAJU SRINIVASsell2,748
Nov 8, 23AKKARAJU SRINIVASother640,688
Nov 8, 23AKKARAJU SRINIVASsell1,750
Coverage · ICPT

Our ICPT coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on ICPT yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate ICPT report →
Internal Compare

Similar companies

Peers in the same neighborhood.